Yosdel Soto

Yosdel Soto

Auto-generated profile, based on publicly available information

Yosdel Soto

Metabolic and Cardiovascular Diseases Laboratory, Division of Human Nutrition, Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
YSYosdel Soto
Yosdel Soto
EAEmilio Acosta
Emilio Acosta
LDLivan Delgado
Livan Delgado
APArlenis Pérez
Arlenis Pérez
VFViviana Falcón
Viviana Falcón
AVAna María Vázquez
Ana María Vázquez
Objective—: Subendothelial retention of proatherogenic lipoproteins by proteoglycans is critical in atherosclerosis. The aim of this study was to characterize the recognition and antiatherogenic properties of a chimeric monoclonal antibody (mAb) that reacts with sulfated molecules. Methods and Results—: chP3R99 mAb recognized sulfated glycosaminoglycans, mainly chondroitin sulfate (CS), by ELISA. This mAb blocked ≈70% of low-density lipoprotein (LDL)–CS association and ≈80% of LDL oxidation in vitro, and when intravenously injected to Sprague-Dawley rats (n=6, 1 mg/animal), it inhibited LDL (4 mg/kg intraperitoneally, 1 hour later) retention and oxidation in the artery wall. Moreover, subcutaneous immunization of New Zealand White rabbits (n=19) with chP3R99 mAb (100 μg, 3 doses at weekly intervals) prevented Lipofundin-induced atherosclerosis (2 mL/kg, 8 days) with a 22-fold reduction in the intima-media ratio ( P <0.01). Histopathologic and ultrastructural studies showed no intimal alterations or slight thickening, with preserved junctions between endothelial cells and scarce collagen fibers and glycosaminoglycans. In addition, immunization with chP3R99 mAb suppressed macrophage infiltration in aorta and preserved redox status. The atheroprotective effect was associated with the induction of anti-CS antibodies in chP3R99-immunized rabbits, capable of blocking CS-LDL binding and LDL oxidation. Conclusion—: These results support the use of anti-sulfated glycosaminoglycan antibody–based immunotherapy as a potential tool to prevent atherosclerosis.

9 June 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
GAGala Araujo
Gala Araujo
LVLeidy Marian Valencia
Leidy Marian Valencia
AMAgata Martin-Ozimek
Agata Martin-Ozimek
YSYosdel Soto
Yosdel Soto
SPSpencer Proctor
Spencer Proctor
Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of lipids, fibrous elements, and cellular debris in the blood vessels. The response-to-retention hypothesis, the leading theory on the pathogenesis of this cardiovascular disease, describes the initial event in atherosclerosis as when Apolipoprotein B-containing lipoproteins, including endogenous and dietary-derived lipoproteins, bind to the inner arterial wall, the tunica intima. The subsequent lipoprotein modifications trigger an immune response that promotes atherosclerotic plaque formation. Despite the prevalence of atherosclerosis globally, and its vascular nature, therapies directed to the artery wall are limited. Immunotherapies, most notably monoclonal antibodies (mAbs), are of special interest due to their high specificity, reliability and proven success in a variety of diseases. However, current mAbs for atherosclerosis tend to target disease risk factors, notably inflammation and circulating lipoprotein levels, rather than address the root cause of atherosclerosis. These treatments result in a phenomenon known as residual risk, defined by the occurrence of severe cardiovascular events, including myocardial infarction, during treatment. Per the “response to retention” hypothesis, a plausible strategy for atherosclerosis would be blocking cholesterol retention per se at the arterial extracellular matrix level to complement lipid-lowering therapies. One such immunotherapy is the chP3R99 mAb, which can bind to pro-atherogenic proteoglycan sugar branches, thus competitively inhibiting lipid retention at these sites. The aim of this review is twofold: 1) To provide a summary of mAbs and other therapies used for atherosclerosis treatment, focusing on anti-inflammatory and lipid-lowering therapies, and 2) To review data on the structural characteristics, theory, and therapeutic effect of the chP3R99 mAb.

1 December 2012 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
VBVíctor Brito
Víctor Brito
KMKatia Mellal
Katia Mellal
SPSimon Giroux Portelance
Simon Giroux Portelance
APArlenis Pérez
Arlenis Pérez
YSYosdel Soto
Yosdel Soto
AVAna María Vázquez
Ana María Vázquez
Objective—: The pathogenesis of atherosclerosis is associated with the early retention of low-density lipoproteins that are trapped in the extracellular matrix of the arterial intima by interaction with glycosaminoglycan side chains of proteoglycans. Mutant mouse/human chimeric antibodies of the murine monoclonal antibody P3, which react with N-glycolyl–containing gangliosides and sulfated glycosaminoglycans, were tested for their potentially antiatherogenic properties through the induction of an idiotypic antibody network that may specifically interfere with the binding of low-density lipoproteins to proteoglycan side chains, low-density lipoprotein modification, and foam cell formation. Methods and Results—: Apolipoprotein E–deficient mice fed a high-fat, high-cholesterol diet received 5 to 6 doses of chP3R99 or chP3S98 mutant antibodies, showing high and low reactivity, respectively, against their respective antigens. Both chimeric antibodies elicited an immunodominant anti-idiotypic response in the absence of adjuvant. A striking (40%–43%) reduction ( P <0.01) in total lesion areas was observed in 18-week-old mice immunized with chP3R99, but not chP3S98, compared with PBS-treated mice. The antiatherosclerotic effect was associated with increased mice sera reactivity against heparin and sulfated glycosaminoglycans, including chondroitin and dermatan sulfate. In addition, purified IgG from chP3R99-immunized mice blocked the retention of apolipoprotein B–containing lipoproteins within the arterial wall of apolipoprotein E −/− mice. Conclusion—: The present study supports use of active immunization and the mounting of an idiotypic antibody network response against glycosaminoglycans as a novel approach to target atherosclerosis.

19 August 2009 in Human Antibodies
Verified
Journal Article
Closed access
YSYosdel Soto
Yosdel Soto
HCHéctor Conde
Héctor Conde
RARonald Aroche
Ronald Aroche
VBVíctor Brito
Víctor Brito
PLPatricia Luaces
Patricia Luaces
ALAna María Vázquez López
Ana María Vázquez López
The relationship between autoantibodies (autoAbs) to oxidized LDL (oxLDL) and coronary artery disease (CAD) remains controversial. IgM and IgG autoAbs to oxLDL and 1-palmitoyl-2 (5'-oxo-valeroyl)-sn-glycero-3-phosphorylcholine (POVPC), as well as the levels of non modified or modified ApoB-100 immune complexes (ICs), were measured in twenty patients undergoing clinically indicated coronary angiography, and in ten young healthy volunteer sera. The levels of IgM autoAbs to oxLDL did not differ between no CAD patients and healthy subjects, but the levels of these autoAbs were significantly higher in no CAD patients and healthy subjects in comparison with CAD patients. There was not difference in the levels of IgM anti-ApoB-100 ICs between both groups of patients. In contrast, the levels of ICs formed by IgM autoAbs and oxidative modified ApoB-100 were lower in patients with CAD than in patients without CAD. No differences were observed in the levels of autoAbs to POVPC among the groups. In conclusion, our results showed that the level of circulating oxLDL IgM autoAbs was lower in CAD patients than in no CAD patients, supporting the hypothesis that this kind of autoAbs might be inversely associated with the presence of atherosclerosis.

1 December 2015 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
LDLivan Delgado-Roche
Livan Delgado-Roche
VBVíctor Brito
Víctor Brito
EAEmilio Acosta
Emilio Acosta
APArlenis Pérez
Arlenis Pérez
JMJulio Raúl Fernández Massó
Julio Raúl Fernández Massó
AVAna M. Vázquez
Ana M. Vázquez

3 September 2014 in mAbs
Verified
Journal Article
Closed access
YSYosdel Soto
Yosdel Soto
NMNiurka Mesa
Niurka Mesa
YAYumisley Alfonso
Yumisley Alfonso
APArlenis Pérez
Arlenis Pérez
FBFernando Batlle
Fernando Batlle
AVAna M Vázquez
Ana M Vázquez
The progression of atherosclerosis is favored by increasing amounts of chondroitin sulfate proteoglycans in the artery wall. We previously reported the reactivity of chP3R99 monoclonal antibody (mAb) with sulfated glycosaminoglycans and its association with the anti-atherogenic properties displayed. Now, we evaluated the accumulation of this mAb in atherosclerotic lesions and its potential use as a probe for specific in vivo detection of the disease. Atherosclerosis was induced in NZW rabbits (n = 14) by the administration of Lipofundin 20% using PBS-receiving animals as control (n = 8). Accumulation of chP3R99 mAb in atherosclerotic lesions was assessed either by immunofluorescence detection of human IgG in fresh-frozen sections of aorta, or by immunoscintigraphy followed by biodistribution of the radiotracer upon administration of 99mTc-chP3R99 mAb. Immunofluorescence studies revealed the presence of chP3R99 mAb in atherosclerotic lesions 24 h after intravenous administration, whereas planar images show...